Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

The renin-angiotensin system in models of pulmonary arterial hypertension vs primary hypertension

Hypertension Research volume 48, pages 2522–2526 (2025)Cite this article

Abstract

Animal models of pulmonary arterial hypertension (PAH) demonstrate up-regulation of the renin angiotensin system. However, no clinical data are available to support the efficacy of angiotensin II inhibition in treatment for PAH. In this mini review, we will update the knowledge regarding regulation of the RAS system in PAH compared to primary hypertension in order to seek better treatments against PAH.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Hassoun PM. Pulmonary arterial hypertension. N Engl J Med. 2021;385:2361–76.

    PubMed  CAS  Google Scholar 

  2. Spiekerkoetter E, Kawut SM, de Jesus Perez VA. New and emerging therapies for pulmonary arterial hypertension. Annu Rev Med. 2019;70:45–59.

    PubMed  CAS  Google Scholar 

  3. Vazquez ZGS, Klinger JR. Guidelines for the treatment of pulmonary arterial hypertension. Lung. 2020;198:581–96.

    PubMed  Google Scholar 

  4. Rosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM. Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation. 2020;141:678–93.

    PubMed  Google Scholar 

  5. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022; https://doi.org/10.1183/13993003.00879-2022):2200879.

  6. Yuan YM, Luo L, Guo Z, Yang M, Ye RS, Luo C. Activation of renin-angiotensin-aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats. J Renin Angiotensin Aldosterone Syst. 2015;16:249–53.

    PubMed  CAS  Google Scholar 

  7. Li G, Liu Y, Zhu Y, Liu A, Xu Y, Li X, et al. ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats. Lung. 2013;191:327–36.

    PubMed  CAS  Google Scholar 

  8. Chen IC, Lin JY, Liu YC, Chai CY, Yeh JL, Hsu JH, et al. Angiotensin-Converting Enzyme 2 activator ameliorates severe pulmonary hypertension in a rat model of left pneumonectomy combined with VEGF inhibition. Front Med. 2021;8:619133.

    Google Scholar 

  9. Chassagne C, Eddahibi S, Adamy C, Rideau D, Marotte F, Dubois-Randé JL, et al. Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol. 2000;22:323–32.

    PubMed  CAS  Google Scholar 

  10. Hu HH, Zhang RF, Dong LL, Chen EG, Ying KJ. Overexpression of ACE2 prevents hypoxia-induced pulmonary hypertension in rats by inhibiting proliferation and immigration of PASMCs. Eur Rev Med Pharm Sci. 2020;24:3968–80.

    Google Scholar 

  11. Hampl V, Herget J, Bíbová J, Baňasová A, Husková Z, Vaňourková Z, et al. Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1-7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia. Physiol Res. 2015;64:25–38.

    PubMed  CAS  Google Scholar 

  12. Bruce E, Shenoy V, Rathinasabapathy A, Espejo A, Horowitz A, Oswalt A, et al. Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. Br J Pharm. 2015;172:2219–31.

    CAS  Google Scholar 

  13. Burrell LM, Gayed D, Griggs K, Patel SK, Velkoska E. Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition. PLoS ONE. 2017;12:e0171975.

    PubMed  PubMed Central  Google Scholar 

  14. Xia H, Feng Y, Obr TD, Hickman PJ, Lazartigues E. Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice. Hypertension. 2009;53:210–6.

    PubMed  CAS  Google Scholar 

  15. Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, et al. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Ren Physiol. 2006;291:F1308–14.

    CAS  Google Scholar 

  16. Takeda Y, Zhu A, Yoneda T, Usukura M, Takata H, Yamagishi M. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens. 2007;20:1119–24.

    PubMed  CAS  Google Scholar 

  17. Zhong JC, Ye JY, Jin HY, Yu X, Yu HM, Zhu DL, et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept. 2011;166:90–7.

    PubMed  CAS  Google Scholar 

  18. Mendoza-Torres E, Oyarzún A, Mondaca-Ruff D, Azocar A, Castro PF, Jalil JE, et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis. 2015;9:217–37.

    PubMed  CAS  Google Scholar 

  19. Patel S, Hussain T. Dimerization of AT(2) and mas receptors in control of blood pressure. Curr Hypertens Rep. 2018;20:41.

    PubMed  PubMed Central  Google Scholar 

  20. Nair SK, Hersh EV, Margulies KB, Daniell H. Clinical studies in Myxomatous Mitral Valve Disease dogs: most prescribed ACEI inhibits ACE2 enzyme activity and ARB increases AngII pool in plasma. Hypertens Res. 2025;4:1477–90. https://doi.org/10.1038/s41440-025-02109-y.

    Article  CAS  Google Scholar 

  21. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. Circ Res. 2016;118:1313–26.

    PubMed  PubMed Central  CAS  Google Scholar 

  22. Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, et al. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol. 2006;291:H2166–72.

    PubMed  CAS  Google Scholar 

  23. Sun X, Wang H, Hodge H, Wright KN, Ahmad S, Ferrario CM, et al. Amplifying effect of chronic lisinopril therapy on diastolic function and the angiotensin-(1-7) Axis by the G1 agonist in ovariectomized spontaneously hypertensive rats. Transl Res. 2021;235:62–76.

    PubMed  CAS  Google Scholar 

  24. Iwanami J, Mogi M, Tsukuda K, Wang XL, Nakaoka H, Ohshima K, et al. Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan. Hypertens Res. 2014;37:616–20.

    PubMed  CAS  Google Scholar 

  25. Inaba S, Iwai M, Furuno M, Kanno H, Senba I, Okayama H, et al. Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition. J Hypertens. 2011;29:2236–45.

    PubMed  CAS  Google Scholar 

  26. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005;280:30113–9.

    PubMed  CAS  Google Scholar 

  27. Narula S, Yusuf S, Chong M, Ramasundarahettige C, Rangarajan S, Bangdiwala SI, et al. Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. Lancet. 2020;396:968–76.

    PubMed  PubMed Central  CAS  Google Scholar 

  28. Uri K, Fagyas M, Manyine Siket I, Kertesz A, Csanadi Z, Sandorfi G, et al. New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. PLoS One. 2014;9:e87845.

    PubMed  PubMed Central  Google Scholar 

  29. Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension. 1995;25:37–46.

    PubMed  CAS  Google Scholar 

  30. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation. 1991;83:1333–42.

    PubMed  CAS  Google Scholar 

  31. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605–10.

    PubMed  CAS  Google Scholar 

  32. Chen L, Kim SM, Eisner C, Oppermann M, Huang Y, Mizel D, et al. Stimulation of renin secretion by angiotensin II blockade is Gsalpha-dependent. J Am Soc Nephrol. 2010;21:986–92.

    PubMed  PubMed Central  CAS  Google Scholar 

  33. Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, et al. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res. 2006;29:865–74.

    PubMed  CAS  Google Scholar 

  34. de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, Francois C, et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186:780–9.

    PubMed  Google Scholar 

  35. Montezano AC, Kuriakose J, Hood KY, Sin YY, Camargo LL, Namkung Y, et al. Ang-(1-7) and ET-1 Interplay Through Mas and ET(B) Receptor interaction defines a novel vasoprotective mechanism. Hypertension. 2025;82:267–81.

    PubMed  CAS  Google Scholar 

  36. Sriramula S, Cardinale JP, Lazartigues E, Francis J. ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc Res. 2011;92:401–8.

    PubMed  PubMed Central  CAS  Google Scholar 

  37. Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, Evora K, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension. 2010;55:90–8.

    PubMed  CAS  Google Scholar 

  38. Rentzsch B, Todiras M, Iliescu R, Popova E, Campos LA, Oliveira ML, et al. Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension. 2008;52:967–73.

    PubMed  CAS  Google Scholar 

  39. Ye M, Wysocki J, Gonzalez-Pacheco FR, Salem M, Evora K, Garcia-Halpin L, et al. Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. Hypertension. 2012;60:730–40.

    PubMed  CAS  Google Scholar 

  40. Dai HL, Guo Y, Guang XF, Xiao ZC, Zhang M, Yin XL. The changes of serum angiotensin-converting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease. Cardiology. 2013;124:208–12.

    PubMed  CAS  Google Scholar 

  41. Li S, Wang Z, Yang X, Hu B, Huang Y, Fan S. Association between circulating angiotensin-converting enzyme 2 and cardiac remodeling in hypertensive patients. Peptides. 2017;90:63–8.

    PubMed  CAS  Google Scholar 

  42. Emilsson V, Gudmundsson EF, Aspelund T, Jonsson BG, Gudjonsson A, Launer LJ, et al. Antihypertensive medication uses and serum ACE2 levels: ACEIs/ARBs treatment does not raise serum levels of ACE2. medRxiv. 2020. https://doi.org/10.1101/2020.05.21.20108738.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Úri K, Fagyas M, Kertész A, Borbély A, Jenei C, Bene O, et al. Circulating ACE2 activity correlates with cardiovascular disease development. J Renin Angiotensin Aldosterone Syst. 2016;17:1470320316668435.

    PubMed  PubMed Central  Google Scholar 

  44. Itelman E, Segel MJ, Kuperstein R, Feinberg M, Segev A, Segal G, et al. Pulmonary hypertension is associated with systemic arterial hypertension among patients with normal left ventricular diastolic function. J Am Heart Assoc. 2021;10:e023603.

    PubMed  PubMed Central  Google Scholar 

  45. Dang Z, Su S, Jin G, Nan X, Ma L, Li Z, et al. Tsantan Sumtang attenuated chronic hypoxia-induced right ventricular structure remodeling and fibrosis by equilibrating local ACE-AngII-AT1R/ACE2-Ang1-7-Mas axis in rat. J Ethnopharmacol. 2020;250:112470.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Heart Institute and Department of Surgery, Morsani College of Medicine, University of South Florida, Room 0815 MDD, 560 Channelside drive, Tampa, FL, 33602, USA

    Yuki Nakayama & Satoru Eguchi

Authors
  1. Yuki Nakayama
    View author publications

    Search author on:PubMed Google Scholar

  2. Satoru Eguchi
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Yuki Nakayama.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakayama, Y., Eguchi, S. The renin-angiotensin system in models of pulmonary arterial hypertension vs primary hypertension. Hypertens Res 48, 2522–2526 (2025). https://doi.org/10.1038/s41440-025-02299-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41440-025-02299-5

Keywords

Search

Advanced search

Quick links